MDS: Medigene CD-TCR-001
A Phase I/II, Open-Label, Non-Randomized,
Multicentre, Dose-Escalation Clinical Trial with
Control Group to Evaluate the Safety, Feasibility and
Preliminary Efficacy of PRAME TCR modified T cells,
MDG1011, in Subjects with High Risk Myeloid and
Lymphoid Neoplasms
Siehe Medigene CD-TCR-001 |